DR. MARY ANN GRAY has been with the Federated Kaufmann Fund for the past
two years, focusing on both public and private healthcare investments.
Prior to joining the Kaufmann Fund, Dr. Gray was a sell side
Biotechnology Analyst for nine years with Kidder Peabody; Dillon, Read;
and Raymond James. Earlier in her career, Dr. Gray managed preclinical
toxicology studies for the National Cancer Institute through Battelle
Memorial Institute and worked in a hospital laboratory. She did
postdoctoral work at Northwestern University Medical School and Yale
University School of Medicine. She held scientific positions at
Schering-Plough and NeoRx. Dr. Gray has a PhD in Pharmacology from the
University of Vermont where she focused on novel chemotherapeutic agents
for the treatment of cancer.
Roundtable Forum: Biotechnology Industry
October 01, 2001